Rowatinex Gastro-resistant Capsules, Soft Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

rowatinex gastro-resistant capsules, soft

rowa pharmaceuticals ltd. - alfa-pinene, beta-pinene, menthol, menthone, borneol, camphene, cineole - capsules gastro-resistant, soft - 24,8mg+6,2mg+15mg+10mg+4mg+4mg+3mg

Rowachol Gastro-resistant Capsules, Soft Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

rowachol gastro-resistant capsules, soft

rowa pharmaceuticals ltd. - alfa-pinene, beta-pinene, menthol, menthone, borneol, camphene, cineole - capsules gastro-resistant, soft - 13,6mg+3,4mg+32mg+6mg+5mg+5mg+2mg

ROWACHOL Israel - English - Ministry of Health

rowachol

megapharm ltd - borneol; camphene; cineole; menthol; menthone; pinene; pinene - capsules - menthol 32 mg; menthone 6 mg; pinene 3.4 mg; borneol 5 mg; camphene 5 mg; cineole 2 mg; pinene 13.6 mg - an adjuvant in the treatment of gall-bladder stones and liver diseases.

SUCRALFATE- sucralfate tablet United States - English - NLM (National Library of Medicine)

sucralfate- sucralfate tablet

pd-rx pharmaceuticals, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - sucralfate is indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate is contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

SUCRALFATE tablet United States - English - NLM (National Library of Medicine)

sucralfate tablet

northwind pharmaceuticals, llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - sucralfate tablets, usp are indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Sucralfate Oral Suspension United States - English - NLM (National Library of Medicine)

sucralfate oral suspension

pharmaceutical associates, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g in 10 ml - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

SUCRALFATE suspension United States - English - NLM (National Library of Medicine)

sucralfate suspension

physicians total care, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g in 10 ml - sucralfate suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. there are no known contraindications to the use of sucralfate.

SUCRALFATE suspension United States - English - NLM (National Library of Medicine)

sucralfate suspension

precision dose inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g in 10 ml - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Sucralfate Oral Suspension United States - English - NLM (National Library of Medicine)

sucralfate oral suspension

vistapharm, llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g in 10 ml - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

SUCRALFATE- sucralfate suspension United States - English - NLM (National Library of Medicine)

sucralfate- sucralfate suspension

cardinal health - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g in 10 ml - sucralfate suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. there are no known contraindications to the use of sucralfate.